Paul Rennie

Degrees / Designations 

B.Sc. (Biochemistry)
Ph.D. (Biochemistry)
Fellow, Canadian Academy of Health Sciences

Mailing Address 
Jack Bell Research Centre 2660 Oak St Vancouver, BC V6H 3Z6


Academic Appointment 
Disorders and Conditions 

Dr. Rennie is a Professor in the Department of Urological Sciences, and co-founder and Director of Laboratory Research for the Vancouver Prostate Centre. He has more than 30 years’ experience in studying the molecular endocrinology of androgen receptors (AR) and prostate cancer and has over 150 peer-reviewed, publications in these areas. In particular, he has considerable experience in the molecular aspects of progression of prostate cancer to castration resistance, AR biochemistry, AR/coactivator interactions, and ligand binding assays.

His lab has had a long history of characterizing hormone regulation of prostate cancers and contributed much of the groundwork for development of widely used, cost-efficient treatments for advanced prostate cancer in the 80’s and for providing the mechanistic basis for intermittent androgen suppression treatment protocols.

Dr. Rennie's current research is aimed at determining how androgens regulate gene transcription and how to use this knowledge to prevent progression to androgen independence in prostate cancers. He is also studying prostate-specific elements of gene promoters and working to develop lenti and herpes virus-based vectors as a targeting vehicle for delivery and prostate-specific expression of genes that can control or kill prostate tumour cells.

Current Projects 

Current funded research projects include:
1) PCF Star Program on androgen receptor extinction as a means to successfully treat prostate cancer (PCF/Safeway) (co-PI)
2) Using Methods of Chemical Genomics for Developing Potent Androgen Receptor Inhibitors with a Novel Mode of Action (Genome BC) (co-PI)
3) In vivo siRNA Knockdown of Androgen Receptors to Treat Advanced Prostate Cancer (CIHR) (co-PI)
4) Next generation anti-androgens for the treatment of castration-resistant prostate cancer (CIHR) (co-PI)
5)Terry Fox Foundation New Frontiers Program on Prostate Cancer Progression (TFRI) (co-PI)
6) Development of Novel Drugs that target co-activations sites of the androgen receptor for treatment of anti-androgen resistant prostate cancer (DOD-US) (co-PI).